GSK plc (NYSE:GSK) shares traded -0.27% lower at $36.76 on Wall Street last session.
In accordance with the data, 23 analysts cover GSK plc (NYSE:GSK). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $62.77 and a low of $30.03, we find $39.80. Given the previous closing price of $36.86, this indicates a potential upside of 7.98 percent. GSK stock price is now 4.91% away from the 50-day moving average and 4.10% away from the 200-day moving average. The market capitalization of the company currently stands at $71.50B.
It has been rated a hold by 11 analysts and a buy by 8. Brokers who have rated the stock have averaged $42.30 as their price target over the next twelve months.
A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GSK stock. A new stake in GSK plc shares was purchased by PROVIDENT TRUST CO during the first quarter worth $66,232,000. SIO CAPITAL MANAGEMENT, LLC invested $17,628,000 in shares of GSK during the first quarter. In the first quarter, INTEGRAL HEALTH ASSET MANAGEMENT, LLC acquired a new stake in GSK plc valued at approximately $12,866,000. JEFFERIES GROUP LLC acquired a new stake in GSK for approximately $10,979,000. GLUSKIN SHEFF & ASSOC INC purchased a new stake in GSK valued at around $8,161,000 in the second quarter. In total, there are 933 active investors with 13.80% ownership of the company’s stock.
GSK plc (NYSE: GSK) opened at $36.72 on Wednesday. During the past 12 months, GSK plc has had a low of $28.47 and a high of $39.74. As of last week, the company has a debt-to-equity ratio of 1.69, a current ratio of 0.90, and a quick ratio of 0.60. According to the stock market information, the enterprise value for the company is $93.84B, which is based on a 11.25 price-to-earnings ratio, a 2.50 price-to-earnings-growth ratio, and a beta of 0.69. The fifty day moving average price for GSK is $35.07 and a two-hundred day moving average price translates $35.33 for the stock.
The latest earnings results from GSK plc (NYSE: GSK) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.97, beating analysts’ expectations of $0.87 by 0.1. This compares to $0.14 EPS in the same period last year. The net profit margin was 52.60% and return on equity was 139.40% for GSK. The company reported revenue of $8.99 billion for the quarter, compared to $8.7 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.31 percent. For the current quarter, analysts expect GSK to generate $9.46B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 10/12/2023. Investors who held shares on 08/18/2023 were paid a $0.361256 dividend. On an annualized basis, this represents a $1.40 dividend and a 3.81% percent yield. There was an ex-dividend date of 08/17/2023 for this dividend.
GSK plc(GSK) Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
